# Synapsys SAS, Marseille, France – FDA Inspections

Source: https://www.keypedia.com/companies/synapsys-sas/2d7929ed-1254-4ee9-b5d1-0fbbab14c3d2

> Inspection records and compliance data for Synapsys SAS in Marseille. 1 FDA inspection on record, 1 Form 483, last inspected October 19, 2017.

---

## Details

- Name: Synapsys SAS
- FEI Number: 3007743829
- Address Line 1: Hotel Technoptic, 2 Rue Marc Donadille
- City: Marseille
- Country Name: France
- Address: Hotel Technoptic, 2 Rue Marc Donadille, Marseille, France
- Country: France

## Related Documents

- [FDA Inspection 1029146 - Synapsys SAS - 2017-10-19](https://www.keypedia.com/records/fda_inspections/synapsys-sas/6038d2e8-ac57-4cda-af5b-880831d9eaf7) — classification: Voluntary Action Indicated (VAI), source: FDA, date: October 19, 2017
- FDA Inspection 1029146 - Synapsys SAS - 2017-10-19 — classification: Voluntary Action Indicated (VAI), source: FDA, date: October 19, 2017

## Related Companies

- [Aspide Medical](https://www.keypedia.com/companies/aspide-medical/9df266a6-110a-4ab5-a0b2-a7ae10e8d797)
- [MEDWIN FRANCE](https://www.keypedia.com/companies/medwin-france/c4066751-3a64-4287-a221-53a9aa50d762)
- [SPS MEDICAL](https://www.keypedia.com/companies/sps-medical/e6b2a0ba-228a-4890-9ec2-4456c08540e7)
- [Jean-Pierre Cebron](https://www.keypedia.com/companies/jean-pierre-cebron/540bb58d-2c28-4e42-81fc-866756d9bb29)
- [Lamidey Noury Medical](https://www.keypedia.com/companies/lamidey-noury-medical/19e89bbd-e43e-4ca4-a53c-e5a70aba1250)
- [Dilon Technologies France SAS](https://www.keypedia.com/companies/dilon-technologies-france-sas/f1278cfd-d85a-4066-969b-6a3c54b69ef7)
- [ACP](https://www.keypedia.com/companies/acp/d37e36b5-14b4-4228-87fa-e9f5dc9378ed)
- [Blue Ortho](https://www.keypedia.com/companies/blue-ortho/f453eb0b-a35a-42ad-b685-379313c8385e)
- [Christophe Pey](https://www.keypedia.com/companies/christophe-pey/d7c1e853-0da1-46e8-b199-eb4eb9eb42d7)
- [MEDICOAT SAS](https://www.keypedia.com/companies/medicoat-sas/5ee03441-ee94-498b-8d7f-4368600befcc)